Publicly Funded, Pegylated Interferon-Alpha Treatment in British Columbia: Disparities in Treatment Patterns for People with Hepatitis C
BACKGROUND: An estimated 60,000 British Columbians are chronically infected with the hepatitis C virus (HCV); 10% to 20% will develop cirrhosis after 20 years and 5% to 10% of these will develop hepatocellular carcinoma. Although treatment may prevent cirrhosis and liver cancer, and improve quality...
Main Authors: | Priscilla C Hsu, Jane A Buxton, Andrew W Tu, Warren D Hill, Amanda Yu, Mel Krajden |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2008-01-01
|
Series: | Canadian Journal of Gastroenterology |
Online Access: | http://dx.doi.org/10.1155/2008/243607 |
Similar Items
-
Long-term pegylated interferon-α and its potential in the treatment of melanoma
by: Reinhard Dummer, et al.
Published: (2009-04-01) -
Pegylated-interferon alpha therapy for treatment-experienced chronic hepatitis B patients.
by: Ming-Lun Yeh, et al.
Published: (2015-01-01) -
Retreatment with Pegylated Interferon Alpha-2a and Ribavirin in Patients with Chronic Hepatitis C Who Have Relapsed or Not Responded to a First Course of Pegylated Interferon-Based Therapy
by: Eric M Yoshida, et al.
Published: (2009-01-01) -
HCV co-infection in HIV positive population in British Columbia, Canada
by: Spinelli John J, et al.
Published: (2010-04-01) -
Research advances in predictors of treatment responses to pegylated interferon alpha in patients with chronic hepatitis B
by: GAO Aihua
Published: (2015-04-01)